Timing of edaravone dexborneol in intravenous thrombolysis with rt-PA for elderly patients with moderate to severe acute ischemic stroke
Objective To investigate the timing of edaravone dexborneol in intravenous thrombolysis with recombi-nant tissue plasminogen activator(rt-PA)for elderly patients with moderate to severe acute ischemic stroke(AIS).Methods A total of 221 patients older than 80 years with moderate to severe AIS receiving intravenous thrombolysis with rt-PA were divided into the control group(70 cases received intravenous thrombolytic therapy with rt-PA),the early group(n=75,edaravone dexborneol began immediately after intravenous thrombolysis with rt-PA)and the late group(n=76,edaravone dexborneol started at 24 h after intravenous thrombolysis with rt-PA).The neurologic improvement rate at 7 days and good prognosis rate at 90 days were used to evaluate the efficacy.The short-term efficacy and long-term efficacy of the three groups were compared.The incidences of symptomatic intracranial hemorrhage within 24 h,extracranial compli-cations within 14 days and mortality within 90 days were observed,and the safety of the three groups was compared.Results The neurologic improvement rate at 7 days and the good prognosis rate at 90 days of the early group and the late group were higher than those of the control group,and those were higher in the early group than in the late group(all P<0.05).The incidences of symptomatic intracranial hemorrhage within 24 h and extracranial complications within 14 days in the early group were lower than those in the late group and control group(all P<0.05),while there were no statisti-cally significant differences between the late group and the control group(all P>0.05).The mortality rates within 90 days of the early and late groups were lower than that of the control group,and that was lower in the early group than in the late group(P<0.05).Conclusion Immediate application of edaravone dexborneol after intravenous thrombolysis with rt-PA is the optimal intervention time for elderly patients with moderate to severe AIS,which can promote the efficacy and safety,reduce complication rate and improve the prognosis of patients.
国家科技期刊平台
NSTL
万方数据
